Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma

Sarcoma

Volumn 2013, Issue , 2013, Pages

  Martin Liberal, Juan ^a   Alam, Salma ^a   Constantinidou, Anastasia ^a   Fisher, Cyril ^a   Khabra, Komel ^b   Messiou, Christina ^a   Olmos, David ^c   Mitchell, Scott ^a   Al Muderis, Omar ^a   Miah, Aisha ^a   Linch, Mark ^a   Jones, Robin L ^a   Scurr, Michelle ^a   Judson, Ian ^a   Benson, Charlotte ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893850818     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2013/868973     Document Type: Article

References (23)

1. van Glabbeke M., Van Oosterom A. T., Oosterhuis J. W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T., Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline- containing first-line regimens-a European organization for research and treatment of cancer soft tissue and bone sarcoma group study. Journal of Clinical Oncology 1999 17 1 150 157 2-s2.0-0032952928 (Pubitemid 29022388)
2. van Oosterom A. T., Mouridsen H. T., Nielsen O. S., Dombernowsky P., Krzemieniecki K., Judson I., Svancarova L., Spooner D., Hermans C., Van Glabbeke M., Verweij J., Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. European Journal of Cancer 2002 38 18 2397 2406 2-s2.0-0036892122 10.1016/S0959-8049(02) 00491-4 (Pubitemid 35387492)
3. Leahy M., Garcia Del Muro X., Reichardt P., Judson I., Staddon A., Verweij J., Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Annals of Oncology 2012 23 10 2763 2770
4. Jones R. L., Fisher C., Al-Muderis O., Judson I. R., Differential sensitivity of liposarcoma subtypes to chemotherapy. European Journal of Cancer 2005 41 18 2853 2860 2-s2.0-28244451952 10.1016/j.ejca.2005.07.023 (Pubitemid 41713123)
5. Neuhaus S. J., Barry P., Clark M. A., Hayes A. J., Fisher C., Thomas J. M., Surgical management of primary recurrent liposarcoma. British Journal of Surgery 2005 92 2 246 252 2-s2.0-13944263235 10.1002/bjs.4802 (Pubitemid 40269344)
6. Crago A. M., Singer S., Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Current Opinion in Oncology 2011 23 4 373 378 2-s2.0-79958857301 10.1097/CCO.0b013e32834796e6
7. Samuels B. L., Chawla S., Patel S., von Mehren M., Hamm J., Kaiser P. E., Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Annals of Oncology 2013 24 6 1703 1709
8. Sleijfer S., Ouali M., van Glabbeke M., Krarup-Hansen A., Rodenhuis S., Le Cesne A., Hogendoorn P. C. W., Verweij J., Blay J.-Y., Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). European Journal of Cancer 2010 46 1 72 83 2-s2.0-71049122368 10.1016/j.ejca.2009.09.022
9. Judson I., van der Graaf W., Verweij J., Results of a randomised phase III trial (EORTC 2012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group [Abstract LBA7]. Proceedings of the ESMO Annual Meeting
10. Lorigan P., Verweij J., Papai Z., Rodenhuis S., Le Cesne A., Leahy M. G., Radford J. A., Van Glabbeke M. M., Kirkpatrick A., Hogendoorn P. C. W., Blay J.-Y., Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. Journal of Clinical Oncology 2007 25 21 3144 3150 2-s2.0-34547688913 10.1200/JCO.2006.09.7717 (Pubitemid 47218064)
11. Boddy A. V., Yule S. M., Wyllie R., Price L., Pearson A. D. J., Idle J. R., Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Research 1993 53 16 3758 3764 2-s2.0-0027327607 (Pubitemid 23252039)
12. Meazza C., Casanova M., Luksch R., Podda M., Favini F., Cefalo G., Massimino M., Ferrari A., Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. Pediatric Blood and Cancer 2010 55 4 617 620 2-s2.0-77957090848 10.1002/pbc.22596
13. Radford J. A., Margison J. M., Swindell R., Lind M. J., Wilkinson P. M., Thatcher N., The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. Journal of Cancer Research and Clinical Oncology 1991 117 4 154 156 2-s2.0-0026327277
14. Benjamin R. S., Legha S. S., Patel S. R., Nicaise C., Single-agent ifosfamide studies in sarcomas of soft tissue and bone. The M.D. Anderson Experience. Cancer Chemotherapy and Pharmacology 1993 31, supplement 2 S174 S179 2-s2.0-0027405598 (Pubitemid 23093328)
15. Leone L., Comandone A., Oliva C., Bussi P., Goffredo F., Bretti S., Bumma C., Stability of ifosfamide in solutions for multiday infusion by external pump. Anti-Cancer Drugs 1995 6 4 604 607 2-s2.0-0029095416
16. Fletcher C. D., Mertens F., WHO Classification of Tumour: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002 Lyon, France IARC Press
17. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference- 5x7.pdf
18. Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009 45 2 228 247 2-s2.0-57849117384 10.1016/j.ejca.2008.10.026
19. Wolbold R., Klein K., Burk O., Nüssler A. K., Neuhaus P., Eichelbaum M., Schwab M., Zanger U. M., Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003 38 4 978 988 2-s2.0-0141532282 10.1053/jhep.2003.50393 (Pubitemid 37221681)
20. Schmidt R., Baumann F., Hanschmann H., Geissler F., Preiss R., Gender difference in ifosfamide metabolism by human liver microsomes. European Journal of Drug Metabolism and Pharmacokinetics 2001 26 3 193 200 2-s2.0-0034779879 (Pubitemid 32988561)
21. Constantinidou A., Jones R. L., Ifosfamide re-challenge in soft-tissue sarcoma. Proceedings of the 16th Annual Meeting Connective Tissue Oncology Society (CTOS '10) 2010
22. Ray-Coquard I., Blay J. Y., Italiano A., Le Cesne A., Penel N., Zhi J., Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. The Lancet Oncology 2012 13 11 1133 1140
23. Dickson M. A., Tap W. D., Keohan M. L., Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Journal of Clinical Oncology 2013 31 16 2024 2028